Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
WASHINGTON, May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. today announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported... | May 25, 2023